Search

Now showing items 1-2 of 2

Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine

Cid-Silva, Purificación; Fernández-Bargiela, Noelia; Margusino-Framiñán, Luis; Balboa-Barreiro, Vanesa; Mena, Álvaro; López-Calvo, Soledad; Vázquez-Rodríguez, Pilar; Martín-Herranz, Isabel; Míguez-Rey, Martín; Poveda, Eva; Castro-Iglesias, Ángeles (Wiley, 2018-11-02)

[Abstract] Two elvitegravir/cobicistat‐based therapies combined with emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) or emtricitabine/tenofovir alafenamide fumarate (EVG/c/FTC/TAF) are currently available for ...

Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study

Fernández-Bargiela, Noelia; Rotea-Salvo, Sandra; Margusino-Framiñán, Luis; Balboa-Barreiro, Vanesa; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles; Mena-De-Cea, Álvaro; López-Calvo, Soledad; Vázquez-Rodríguez, Pilar; Míguez-Rey, Enrique; Cid-Silva, Purificación (BMJ, 2020-10-13)

[Abstract] Objectives: Despite the high efficacy of antiretroviral treatment, no drug is free from adverse events (AEs). Efavirenz (EFV) and dolutegravir (DTG) are antiretroviral drugs for which neuropsychiatric adverse ...